Lower baseline PSA predicts greater benefit from sipuleucel-T.
Yale Cancer Center, New Haven, Connecticut.
Daniel
D
Petrylak
D000230:Adenocarcinoma / Q000097:blood* / Q000628:therapy*; D019496:Cancer Vaccines / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000628:therapy*; D014020:Tissue Extracts / Q000627:therapeutic use*
D019496:Cancer Vaccines; D014020:Tissue Extracts; D017430:Prostate-Specific Antigen